|PO Box 208042
New Haven, CT 06520-8042
Admin Assistant, Lisa Hribko
The Yale-New Haven Hospital Nuclear Medicine Clinical Service, located in the new Smilow Cancer Hospital, provides many essential nuclear medicine studies for evaluation of infections, bone metastases, fractures, acute and chronic cholecystitis, scans for hyperparathyroid adenoma, congenital hypothyroidism, hyperthyroidism, cold nodules, extent of thyroid carcinoma involvement, and neuroendocrine tumor detection.
New additions include DaTscan (Ioflupane) scan for evaluation and differentiation of essential tremor from tremor due to PS (idiopathic Parkinson's disease, multiple system atrophy and progressive supranuclear palsy), Amyvid scans for suspected Alzheimer patients, Ra-223 therapy for bone pain palliation introduced in July 2013 as the first center to give this treatment in the state of Connecticut. We also provide studies for evaluation of differential renal function, renovascular disease, and UPJ obstruction, portal hypertension, gastrointestinal bleed localization, lung scan for differential lung function and pulmonary embolism, as well as tumor staging. and seizure focus localization using PET/CT scan. In terms of therapeutic treatments, we provide radioimmunotherapies, bone pain palliation, as well as radioiodine treatments for thyroid carcinoma patients.
There are 3 major services that place YNHH apart from most other hospitals in Connecticut. We have 2 PET/CT scanners with LySO crystal, one of which is equipped with state-of-the-art 64-slice CT, time of flight and respiratory gating. We have the highest volume of PET/CT studies and radioiodine treatments in the state. We get referrals from all over the state of CT, as well as from MA, NY and NJ. With a close working relationship with Dr. Udelsman, the chairman of Yale Department of Surgery, we have one of the highest sensitivity in parathyroid imaging in the country. We intend to keep improving the quality of our services to help our colleagues with theirs. Since 2008, we have established a Nuclear Medicine Consultation Clinic where we dedicate time to assess and to discuss radiation safety precautions with each patient.
The research mission of the Nuclear Medicine Division is realized through the formation of the Yale University Positron Emission Tomography Center (PET Center). The PET Center is being used to advance the interests of Yale clinicians, scientists and students in molecular imaging. The only focus of the PET Center is to conduct scientific research in human subjects and experimental animals. A new Siemens whole body PET/CT scanner with 128 slices CT has been added to the PET center for oncology and other research projects. There is a high-resolution brain PET scanner (Siemens HRRT), a whole body PET scanner, and a micro PET scanner in operation.
It is anticipated that the PET Center will develop interdepartmental scientific collaborations within the School of Medicine but also creates ties to basic science departments in the wider Yale University community in order to advance basic scientific research and participate in the education of doctoral and postdoctoral trainees.
- Molecular imaging and therapy
- PET and MR imaging
- Improving PET/CT imaging acquisition and quantification
- Validation of new clinical radiotracer
- Radiation exposure assessment
- Internal dosimetry
- Radioiodine treatment for thyroid disease
- Molecular imaging in neuroscience and neurotoxicology
- Small animal imaging, receptor binding assay and autoradiography
- Imaging Biomarkers
- Radioproteomics and Radiogenomics
- Clinical applications of positron imaging and single photon imaging in oncology and non-oncology areas
- Radio-targeted therapy
Boustani AM, Pucar D, Saperstein L: Molecular imaging of prostate cancer. Br J Radiol. 2018 Apr; 2018 Feb 1. PMID: 29243485
Pucar D, Boustani AM, Bronen RA, Saperstein L: Superior Pituitary Border Analysis in Immunotherapy-Induced Hypophysitis. Clin Nucl Med. 2018 Apr. PMID: 29401149
Morbelli S, Arbizu J, Booij J, Chen MK, Chetelat G, Cross DJ, Djekidel M, Drzezga A, Ekmekcioglu O, Garibotto V, Hesse S, Ishii K, Jafari L, Lammertsma AA, Law I, Mathews D, Minoshima S, Mosci K, Pagani M, Pappata S, Silverman DH, Signore A, Van De Giessen E, Villemagne V, Barthel H, European Association of Nuclear Medicine (EANM) and of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).: Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18 F]FDG PET: the autoimmune encephalitis. Eur J Nucl Med Mol Imaging. 2017 Mar. PMID: 27987029
Morbelli S, Arbizu J, Booij J, Chen MK, Chetelat G, Cross DJ, Djekidel M, Drzezga A, Ekmekcioglu O, Garibotto V, Hesse S, Ishii K, Jafari L, Lammertsma AA, Law I, Mathews D, Minoshima S, Mosci K, Pagani M, Pappata S, Silverman DH, Signore A, Van De Giessen E, Villemagne V, Barthel H, European Association of Nuclear Medicine (EANM) and of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).: The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis. Eur J Nucl Med Mol Imaging. 2017 Mar; 2016 Dec 6. PMID: 27924371
Finnema SJ, Nabulsi NB, Mercier J, Lin SF, Chen MK, Matuskey D, Gallezot JD, Henry S, Hannestad J, Huang Y, Carson RE: Kinetic evaluation and test-retest reproducibility of [11C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans. J Cereb Blood Flow Metab. 2017 Jan 1; 2017 Jan 1. PMID: 28792356
Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin SF, Chen MK, Dhaher R, Matuskey D, Baum E, Holden D, Spencer DD, Mercier J, Hannestad J, Huang Y, Carson RE: Imaging synaptic density in the living human brain. Sci Transl Med. 2016 Jul 20. PMID: 27440727
Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, Staugaard C, Indukala D, Boustani AM, Patel V, Cha CH, Salem RR, Chang B, Hochster HS, Lacy J: Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer. 2016 Mar 29. PMID: 27022826
Chen MK, Menard DH 3rd, Cheng DW: Determining the Minimal Required Radioactivity of 18F-FDG for Reliable Semiquantification in PET/CT Imaging: A Phantom Study. J Nucl Med Technol. 2016 Mar; 2016 Jan 14. PMID: 26769598
Park E, Gallezot JD, Delgadillo A, Liu S, Planeta B, Lin SF, O'Connor KC, Lim K, Lee JY, Chastre A, Chen MK, Seneca N, Leppert D, Huang Y, Carson RE, Pelletier D: (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. Eur J Nucl Med Mol Imaging. 2015 Jun; 2015 Apr 2. PMID: 25833352
Lin SF, Labaree D, Chen MK, Holden D, Gallezot JD, Kapinos M, Teng JK, Najafzadeh S, Plisson C, Rabiner EA, Gunn RN, Carson RE, Huang Y: Further evaluation of [11C]MP-10 as a radiotracer for phosphodiesterase 10A: PET imaging study in rhesus monkeys and brain tissue metabolite analysis. Synapse. 2015 Feb; 2014 Dec 11. PMID: 25450608
Chen MK, Cheng DW: What is the role of dosimetry in patients with advanced thyroid cancer? Curr Opin Oncol. 2015 Jan. PMID: 25319079
Caporizzo DJ, Kwiatkowski AE, Chen MK, Beck AP, Booth CJ, Zeiss C, Smith PC, Carlson Scholz JA, Wilson SR: Use of (18)F-fluorodeoxyglucose positron emission tomography-computed tomography to aid in diagnosing intestinal adenocarcinoma in 2 rhesus macaques (Macaca mulatta). Comp Med. 2014 Jun. PMID: 24956213
Thut DP, Kreychman A, Obando JA: ¹¹¹In-DTPA cisternography with SPECT/CT for the evaluation of normal pressure hydrocephalus. J Nucl Med Technol. 2014 Mar; 2014 Jan 24. PMID: 24463341
Chen MK, Yasrebi M, Samii J, Staib LH, Doddamane I, Cheng DW: The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer. Thyroid. 2012 Mar; 2012 Feb 2. PMID: 22300251
Chen MK, Doddamane I, Cheng DW: Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management. Curr Opin Oncol. 2010 Jan. PMID: 19844179